NDUFB5
ENSG00000136521
Target class
Enzyme
Chromosome
3
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFB5
- Gene name
- NADH:ubiquinone oxidoreductase subunit B5
- Gene symbol
- NDUFB5
- Protein name
- NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial (Complex I-SGDH) (CI-SGDH) (NADH-ubiquinone oxidoreductase SGDH subunit)
- SGDH
- CI-SGDH
- MGC12314
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 44.13
- Tissue specificity (Gini)
- 0.154
- Tissue specificity (tau)
- 0.421
- KEGG gene identifiers
- hsa:4711
- Protein interaction confidence
- 0.927528
- Protein interaction partners
- 108
- R-HSA-611105
- R-HSA-6799198
- End position
- 179627647
- Start position
- 179604690
- Chromosome
- 3
- Strand
- Forward
- Mitochondrion inner membrane
- Single-pass membrane protein
- Matrix side .
- Mitochondria
Publication evidence
- PubMed 12611891
- Tissue specificity (tau)
- 0.420725
- Expression inequality (Gini)
- 0.153741
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 44.13
- Heart - Left Ventricle
- 41.92
- Muscle - Skeletal
- 38.77
- Cells - EBV-transformed lymphocytes
- 37.77
- Brain - Cerebellar Hemisphere
- 37.58
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)44.13
- Heart - Left Ventricle41.92
- Muscle - Skeletal38.77
- Cells - EBV-transformed lymphocytes37.77
- Brain - Cerebellar Hemisphere37.58
- Heart - Atrial Appendage35.86
- Brain - Cortex35.62
- Brain - Cerebellum34.62
- Kidney - Medulla34.21
- Adrenal Gland34.12
- Brain - Nucleus accumbens (basal ganglia)32.98
- Colon - Sigmoid32.74
- Brain - Anterior cingulate cortex (BA24)31.19
- Brain - Caudate (basal ganglia)29.7
- Bladder29.6
- Cells - Cultured fibroblasts27.85
- Thyroid27.29
- Esophagus - Muscularis27.05
- Brain - Spinal cord (cervical c-1)26.99
- Colon - Transverse26.89
- Brain - Hypothalamus26.76
- Testis26.44
- Adipose - Visceral (Omentum)26.12
- Brain - Substantia nigra25.81
- Brain - Putamen (basal ganglia)25.55
And 29 more, listed on the interactive page.
Biological processes
- GO:0006120
- GO:0005739
- GO:0005743
- GO:0045271
- GO:0005515
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor